Blood, the Journal of the American Society of Hematology (ASH) has published "Clinical and immunologic impact of CCR5 blockade" by CCTI principal investigator and Associate Professor of Medicine, Dr. Ran Reshef, et al. The paper discusses graft-versus-host disease (GVHD) as a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Additionally, lymphocyte trafficking via chemokine receptors such as CCR5 play a critical role in alloreactive responses, and previous data suggest that CCR5 blockade with maraviroc results in a low incidence of visceral GVHD. Click here for the online publication in Blood.